Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

BACC Bay Tocilizumab Trial, 2020 NCT04356937

tocilizumab (n=161) vs. placebo (n=81)

randomized controlled trial   low risk of bias

Studied treatment

Tocilizumab
Tocilizumab single dose (8 mg per kilogram of body weight administered intravenously, not to exceed 800 mg) plus standard of care.

Control treatment

Placebo

Patients

COVID 19 all comers

Age > 18 and < 80 years old, Male or female gender, Confirmed SARS-CoV-2 infection by NP swab PCR, Admitted to non-ICU level care at MGH WITH evidence of severe COVID-19 (at least 2 of the following): Fever > 38C, Pulmonary infiltrates on chest X ray, Need for supplemental O2 to maintain saturation > 92% AND at least 1 of the following: Ferritin > 500 ng/ml, CRP > 50 mg/L, LDH >250 U/L, D-dimer > 1000 ng/mL.

Method

Double-blind.

7 Boston hospitals, United States.

Remark

TOCOVID, 0 NCT04332094

tocilizumab (n=136) vs. standard of care (n=134)

randomized controlled trial   risk of bias NA

Studied treatment

experimental: intervention early administration of tocilizumab associated with hydroxychloroquine and azithromycin
tocilizumab 162 mg sc x 2 doses tocilizumab 162mg sc x 2 doses at 12 hours (day 1)hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days

Control treatment

hydroxychloroquine and azithromycin
hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days

Patients

COVID 19 all comers

Method

open-label

Spain

pilot, randomized, multicenter, open-label clinical trial

Remark